REGEN
Get REGENGet Now
LibraryToolsNotesBlogFAQ

SLU-PP-332 Side Effects and Safety

Reported SLU-PP-332 side effects, contraindications, and safety signals.

RE
Compiled from published research · Last updated 2026-08-18T00:00:00.000Z

No Human Safety Data

Because no human trial has been published, there is no characterized human side-effect profile for SLU-PP-332. Active malignancy is treated as a precautionary contraindication given the broad nuclear-receptor mechanism affecting cellular metabolism genome-wide.

Contraindications

  • pregnancy
  • active malignancy

References

  1. SLU-PP-332 pan-ERR agonist metabolic syndrome study · Billon C, et al. · 2024
All SLU-PP-332 sections

SLU-PP-915

longevity & healthspanDgrade

The first orally-active pan-ERR agonist — raised exercise capacity in mice even when dosed orally, where its predecessor SLU-PP-332 needed injection.

Thymosin Alpha-1

longevity & healthspanAgrade

A 28-amino-acid thymic peptide approved in 35+ countries as Zadaxin for immune support — but never FDA-approved in the United States.

Oxytocin

longevity & healthspanBgrade

A naturally occurring nonapeptide — FDA-approved as Pitocin for labor, and separately studied off-label (intranasal) for social bonding and stress research.

Put the whole protocol
in one place.

Download nowGet Now